8-K

TENET HEALTHCARE CORP (THC)

8-K 2025-05-27 For: 2025-05-22
View Original
Added on April 07, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

_______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report: May 22, 2025

(Date of earliest event reported)

_______________

TENET HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada 1-7293 95-2557091
(State of Incorporation) (Commission File Number) (IRS Employer<br>Identification Number)

_______________

14201 Dallas Parkway

Dallas, TX 75254

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

_______________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading<br>Symbol(s) Name of each exchange <br>on which registered
Common stock, $0.05 par value THC NYSE
6.875% Senior Notes due 2031 THC31 NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2025 Annual Meeting of Shareholders (the “Annual Meeting”) of Tenet Healthcare Corporation (the “Company”) was held on May 22, 2025. Below are the final voting results from the meeting.

1.    The Company’s shareholders elected the following directors to serve on the Company’s Board of Directors, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected or qualified, whichever is later, or until the director’s earlier resignation or removal:

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
Saumya Sutaria 75,129,573 3,175,124 41,625 7,527,011
J. Robert Kerrey 76,518,701 1,792,925 34,696 7,527,011
Vineeta Agarwala 78,006,611 308,065 31,646 7,527,011
James L. Bierman 77,926,307 387,722 32,293 7,527,011
Roy Blunt 77,882,738 431,663 31,921 7,527,011
Richard W. Fisher 77,904,115 409,618 32,589 7,527,011
Meghan M. FitzGerald 77,624,893 691,419 30,010 7,527,011
Cecil D. Haney 77,887,930 401,532 56,860 7,527,011
Christopher S. Lynch 77,995,490 318,301 32,531 7,527,011
Richard J. Mark 77,978,174 334,968 33,180 7,527,011
Tammy Romo 75,980,163 2,335,099 31,060 7,527,011
Stephen H. Rusckowski 77,992,021 321,640 32,661 7,527,011
Nadja Y. West 77,762,668 529,830 53,824 7,527,011

2.    The Company’s shareholders approved, on an advisory basis, the Company’s executive compensation:

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
72,929,010 5,362,708 54,604 7,527,011

3.    The Company’s shareholders approved the ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2025:

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
85,288,950 538,057 46,326

4.    The shareholder proposal requesting a report on strategies and programs for improving maternal health outcomes did not pass.

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
3,845,664 73,121,521 1,379,137 7,527,011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TENET HEALTHCARE CORPORATION
Date: May 27, 2025 By: /s/ THOMAS ARNST
Name: Thomas Arnst
Title: Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary